Conv. Plasma
Nigella Sativa

All colchicine studies
Meta analysis
study COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Ventilation 25% Colchicine for COVID-19  Salah et al.  META ANALYSIS Favors colchicine Favors control

Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19

Salah et al., The American Journal of Cardiology, doi:10.1016/j.amjcard.2021.02.005
Apr 2021  
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Meta analysis of 8 studies, showing significantly lower COVID-19 mortality with colchicine.
10 meta analyses show significant improvements with colchicine for mortality Danjuma, Elshafei, Elshiwy, Golpour, Lien, Rai, Salah, Zein, oxygen therapy Elshiwy, hospitalization Kow, and severity Yasmin.
Currently there are 54 colchicine for COVID-19 studies, showing 29% lower mortality [19‑39%], 29% lower ventilation [-15‑56%], 34% lower ICU admission [8‑52%], 19% lower hospitalization [11‑26%], and 9% more cases [-8‑29%].
risk of death, 38.0% lower, RR 0.62, p < 0.001.
risk of mechanical ventilation, 25.0% lower, RR 0.75, p = 0.27.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Salah et al., 30 Apr 2021, peer-reviewed, 2 authors.
This PaperColchicineAll
Abstract: 170 The American Journal of Cardiology ( time frame analysis showed a significant drop in hospitalization rates just after PC encounters, and continued to decrease over time (Panel A). The annual trends for 90-day all-cause hospitalization rates before PC encounters showed a significant reduction over time (59.7% in 2010 to 53.3% in 2018, p <0.001), but hospitalization rates after PC remained stable over the study period (Panel B). In this observational nationwide analysis of over 25,000 acute on chronic HF admissions, PC encounters were associated with a significant reduction in all-cause, HF-specific, and non-HF 90-day hospitalization rates. This reduction was noted immediately after discharge from the index admission with a PC encounter. Hospitalization rates before PC utilization decreased over the study period perhaps due to the early recognition of value of PC among these sick patients. This study is limited by the nature of this administrative database which carries a risk of mis- or under-coding. Additionally, we could not identify patients who died after hospital discharge. Some of the reduction in readmission may be due to this factor. However, it is unlikely that death would account for the entire decrease in admission rates after a hospital PC consultation, since not all patients seen by PC physicians are appropriate for hospice or accept a palliative approach to care, and the previously reported post-HF discharge 30-day mortality rate »7% (1). Moreover, the philosophical change of care to a palliative approach encourages a decrease in low-value health care utilization such as repeat hospital admissions at the end of life. In summary, we found that patients who received a PC encounter during a hospitalization had a reduction in subsequent readmission rates. Further studies should assess the competing risk of death in this population. Disclosure: The authors have nothing to disclose, and no relationship with industry. Funding: Self-funded Ahmed Elkaryoni, MDa,* Brett W. Sperry, MDb Anna Royce, MDc Kevin Walsh, MDd Elizabeth Bruno, MDd Subir Shah, DOa,d Amir Darki, MD MSca,d Islam Y. Elgendy, MDe a Division of Cardiovascular Disease, Loyola University Medical Center, Loyola Stritch School of Medicine, Maywood, Illinois b Division of Cardiovascular Disease, Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri c Department of Internal Medicine, University of Oklahoma, Oklahoma d Department of Internal Medicine, Loyola University Medical Center, Loyola Stritch School of Medicine, Maywood, Illinois e Divison of Cardiology, Weill Cornell MedicineQatar, Doha, Qatar 27 January 2021 1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics2020 update: a report from the American Heart Association. Circulation 2020;141:e139–e596. 2. Diop MS, Bowen GS, Jiang L, Wu WC, Cornell PY, Gozalo P, Rudolph JL...
{ 'DOI': '10.1016/j.amjcard.2021.02.005', 'ISSN': ['0002-9149'], 'URL': '', 'alternative-id': ['S0002914921001429'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Meta-analysis of the Effect of Colchicine on Mortality and Mechanical ' 'Ventilation in COVID-19'}, { 'label': 'Journal Title', 'name': 'journaltitle', 'value': 'The American Journal of Cardiology'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': ''}, {'label': 'Content Type', 'name': 'content_type', 'value': 'simple-article'}, {'label': 'Copyright', 'name': 'copyright', 'value': 'Published by Elsevier Inc.'}], 'author': [ {'affiliation': [], 'family': 'Salah', 'given': 'Husam M.', 'sequence': 'first'}, { 'ORCID': '', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Mehta', 'given': 'Jawahar L.', 'sequence': 'additional'}], 'container-title': 'The American Journal of Cardiology', 'container-title-short': 'The American Journal of Cardiology', 'content-domain': { 'crossmark-restriction': True, 'domain': [ '', '', '', '', '', '', '', '']}, 'created': {'date-parts': [[2021, 2, 19]], 'date-time': '2021-02-19T20:30:37Z', 'timestamp': 1613766637000}, 'deposited': { 'date-parts': [[2021, 3, 23]], 'date-time': '2021-03-23T10:19:48Z', 'timestamp': 1616494788000}, 'indexed': {'date-parts': [[2023, 5, 15]], 'date-time': '2023-05-15T09:12:35Z', 'timestamp': 1684141955158}, 'is-referenced-by-count': 19, 'issued': {'date-parts': [[2021, 4]]}, 'language': 'en', 'license': [ { 'URL': '', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 4, 1]], 'date-time': '2021-04-01T00:00:00Z', 'timestamp': 1617235200000}}], 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': '170-172', 'prefix': '10.1016', 'published': {'date-parts': [[2021, 4]]}, 'published-print': {'date-parts': [[2021, 4]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.1007/s40495-020-00225-6', 'article-title': 'Colchicine in COVID-19: an old drug, new use', 'author': 'Schlesinger', 'doi-asserted-by': 'crossref', 'first-page': '137', 'journal-title': 'Curr Pharmacol Rep', 'key': '10.1016/j.amjcard.2021.02.005_bib0001', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1016/j.yexcr.2009.08.020', 'article-title': 'Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling ' 'pathway', 'author': 'Jackman', 'doi-asserted-by': 'crossref', 'first-page': '3242', 'journal-title': 'Exp Cell Res', 'key': '10.1016/j.amjcard.2021.02.005_bib0002', 'volume': '315', 'year': '2009'}, { 'DOI': '10.1002/cmdc.201800641', 'article-title': 'Synthesis, biological evaluation, and molecular docking of ' 'combretastatin and colchicine derivatives and their hCE1-activated ' 'prodrugs as antiviral agents', 'author': 'Richter', 'doi-asserted-by': 'crossref', 'first-page': '469', 'journal-title': 'ChemMedChem', 'key': '10.1016/j.amjcard.2021.02.005_bib0003', 'volume': '14', 'year': '2019'}, { 'DOI': '10.1001/jamanetworkopen.2020.13136', 'article-title': 'Effect of colchicine vs standard care on cardiac and inflammatory ' 'biomarkers and clinical outcomes in patients hospitalized with ' 'coronavirus disease 2019: the GRECCO-19 randomized clinical trial', 'author': 'Deftereos', 'doi-asserted-by': 'crossref', 'journal-title': 'JAMA Netw Open', 'key': '10.1016/j.amjcard.2021.02.005_bib0004', 'volume': '3', 'year': '2020'}, { 'DOI': '10.1016/j.hjc.2020.11.012', 'article-title': 'Impact of colchicine on mortality in patients with COVID-19. A ' 'meta-analysis', 'author': 'Vrachatis', 'doi-asserted-by': 'crossref', 'journal-title': 'Hellenic J Cardiol', 'key': '10.1016/j.amjcard.2021.02.005_bib0005', 'year': '2021'}, { 'DOI': '10.1136/annrheumdis-2020-217712', 'article-title': 'Association between treatment with colchicine and improved survival in ' 'a single-centre cohort of adult hospitalised patients with COVID-19 ' 'pneumonia and acute respiratory distress syndrome', 'author': 'Scarsi', 'doi-asserted-by': 'crossref', 'first-page': '1286', 'journal-title': 'Ann Rheum Dis', 'key': '10.1016/j.amjcard.2021.02.005_bib0006', 'volume': '79', 'year': '2020'}, { 'DOI': '10.1155/2020/8865954', 'article-title': 'A case control study to evaluate the impact of colchicine on patients ' 'admitted to the hospital with moderate to severe COVID-19 infection', 'author': 'Sandhu', 'doi-asserted-by': 'crossref', 'journal-title': 'Can J Infect Dis Med Microbiol', 'key': '10.1016/j.amjcard.2021.02.005_bib0007', 'volume': '2020', 'year': '2020'}, { 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID-19: an ' 'interim analysis of a randomized, double-blinded, placebo controlled ' 'clinical trial', 'author': 'Lopes', 'journal-title': 'medRxiv', 'key': '10.1016/j.amjcard.2021.02.005_bib0008', 'year': '2020'}, { 'DOI': '10.5005/jp-journals-10071-23599', 'article-title': 'A retrospective observational study of hypoxic COVID-19 patients ' 'treated with immunomodulatory drugs in a Tertiary Care Hospital', 'author': 'Mahale', 'doi-asserted-by': 'crossref', 'first-page': '1020', 'journal-title': 'Indian J Crit Care Med', 'key': '10.1016/j.amjcard.2021.02.005_bib0009', 'volume': '24', 'year': '2020'}, { 'DOI': '10.3390/jcm9092961', 'article-title': 'Colchicine to weather the cytokine storm in hospitalized patients with ' 'COVID-19', 'author': 'Brunetti', 'doi-asserted-by': 'crossref', 'first-page': '2961', 'journal-title': 'J Clin Med', 'key': '10.1016/j.amjcard.2021.02.005_bib0010', 'volume': '9', 'year': '2020'}, { 'article-title': 'Efficacy of colchicine in non-hospitalized patients with COVID-19', 'author': 'Tardif', 'journal-title': 'medRxiv', 'key': '10.1016/j.amjcard.2021.02.005_bib0011', 'year': '2021'}, { 'article-title': 'Clinical outcome of patients with COVID-19 pneumonia treated with ' 'corticosteroids and colchicine in Colombia', 'author': 'Pinzón MA', 'journal-title': 'Res Sqaure', 'key': '10.1016/j.amjcard.2021.02.005_bib0012', 'year': '2020'}], 'reference-count': 12, 'references-count': 12, 'relation': {}, 'resource': {'primary': {'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Cardiology and Cardiovascular Medicine'], 'subtitle': [], 'title': 'Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19', 'type': 'journal-article', 'update-policy': '', 'volume': '145'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop